Eisai Inc. (ESALY) and Merck (MRK) announced that the U.S. FDA approved the kinase inhibitor LENVIMA for the first-line treatment of patients with unresectable hepatocellular carcinoma. This approval was based on results from REFLECT, where LENVIMA demonstrated a proven treatment effect on overall survival by statistical confirmation of non-inferiority, as well as statistically significant superiority and clinically meaningful improvements in progression-free survival and objective response rate when compared with sorafenib in patients with previously untreated unresectable HCC.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.